ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 1626.0 | 1421.6 | 1302.7 |
| Other income | 70.9 | 61.4 | 26.3 |
| Total income | 1696.9 | 1483.1 | 1329.0 |
| Profit before exceptional items & tax | 446.8 | 347.1 | 331.1 |
| Profit before tax | 446.8 | 347.1 | 331.1 |
| Net profit | 334.2 | 266.7 | 255.3 |
| Operating margin | 26.3% | 23.4% | 24.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +30.90% |
|---|---|
| Net profit, quarter on quarter | +25.30% |
| Revenue, year on year | +24.80% |
| Operating profit, year on year | +15.00% |
| Operating profit, quarter on quarter | +28.30% |
BSE results filing, NSE: AJANTPHARM. Figures extracted from the filing.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,319.60
- Market cap
- ₹41,481 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 32.9×Sector 43.8×
- Promoter holding
- 63.47%-0.01% QoQ
- FII holding
- 7.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Earnings Call Transcript: Key Takeaways
Ajanta Pharma posted robust revenue and PAT growth, primarily driven by a temporary US market upside. Management remains cautious as competition intensifies.
- Call
- Guides 18% growth
Ajanta Pharma Q2 FY27 Results: Net Profit ₹388.1 Cr, Up 49.2% YoY
Ajanta Pharma Ltd reported revenue from operations of ₹1,794 Cr (+32.5% YoY) and net profit of ₹388.1 Cr (+49.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹388.1 Cr · +49.2% YoY
Ajanta Pharma Share Pledge
Ajanta Pharma promoter Aayush Agrawal (trustee) created a pledge on 30,000 equity shares. The pledge was made as a top-up call due to share price reduction.
Ajanta Pharma Board Meeting Date
Ajanta Pharma has scheduled a Board meeting for 30 October 2026 to consider Q2/H1 2026 unaudited financial results. No material decision has been taken yet.
Ajanta Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Ajanta Pharma Share Pledge
Promoter Aayush Agrawal Trust created pledge on 4,60,000 Ajanta Pharma shares. The pledge secures an NCD issue in favor of CTL Trusteeship Ltd.